Japanese SearchCareersSitemapContact
Autologous Immune Enhancement Therapy and its potentials; ATRO guest lecture by NCRM delegation

African-Asian cancer meet calls for more research in India

Friday, February 22, 2013

Bangalore: An African-Asian conference on transitional research in oncology on Friday called for collaborative cancer treatment with personalised care and a repository of cancer-based research in India.

“India has immense potential to be a leader in oncology research due to a growing number of cancer patients. In the absence of research, we have been depending on western data and guidelines to tackle the problem,” Association for Transitional Research in Oncology president Dr B S Ajaikumar said at a three-day conference here.

According to the latest population-based cancer registry, cancer incidence for every 100,000 males and females in key cities across the country like Bangalore is 113/139, New Delhi has 124/121 and Mumbai 99/110.

“With Bangalore having the highest incidence of cancer cases in the country, there is an urgent need for superior cancer care for patients through futuristic technology to improve their quality of life,” said Dr Ajaikumar in a daylong session on combating the dreaded disease.

Oncologists from Asia and Africa are holding brainstorming sessions on personalised medicine, organ and functional preservation in breast cancer, haematology and stem cell transplant and cardiothoracic oncology at the conference on ‘From Bedside to Benchmark’, organised by the association.

“One of the emerging challenges in oncology is the utilization of patient-specific genomic information to develop personalized and targeted therapeutic options based on molecular aberrations in the tumour,” medical oncologist Dr Prahlad Ram of the US-based Anderson Cancer Centre said in his presentation.

The second challenge facing cancer medicine is the identification of pharmacological options to overcome resistance and repurposing of approved drugs for cancer therapy.

“In the human immune surveillance system, a combination of adaptive and innate pathways work together to tackle cancer,” said surgical oncologist Dr Samuel J K Abraham from Japan’s Yamanashi University.

When functioning optimally, the immune system destroys any aberrant cell, which might evolve into a cancer. The dysfunction of the system against a strong causative factor culminates in cancer development.

“One of the therapy aims is to empower the autologous immune cells to treat a diagnosed cancer and prevent cancer development as well its recurrence,” Dr Abraham said.

Over the next two days, the conference will focus on predictive oncology, colorectal and liver cancer, radiation oncology, neuro-oncology, psycho-oncology, gynaecology-oncology, head and neck cancer, evolving comprehensive cancer, global perspectives in oncology, lung cancer, musculoskeletal oncology and uro-oncology.

“There are about 30 million cancer survivors worldwide, which are expected to jump to 70 million by 2050. We aim to bring together oncologists to discuss preventive care and improved treatment, to advance the quality of life of cancer patients and survivors across the country.”

The association of specialists in multi-disciplinary areas works as a platform to promote transitional research in oncology. [Source: IANS]



- Courtesy Aala Times.com, 22nd Feb 2013 issue.
*"Nichi" stands for Japan and "In" stands for India. This institute started on an Indo-Japan collaboration now has spreaded further with global alliances
    © NCRM. All right reserved.                                                                                                                                                                                          Disclaimer